Privium Fund Management B.V. Increases Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Privium Fund Management B.V. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 125.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,709 shares of the company’s stock after buying an additional 15,409 shares during the period. Privium Fund Management B.V.’s holdings in Intellia Therapeutics were worth $323,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the fourth quarter worth about $40,000. KBC Group NV boosted its position in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Intellia Therapeutics by 80.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after purchasing an additional 2,299 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new position in Intellia Therapeutics during the 3rd quarter valued at approximately $151,000. 88.77% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NTLA has been the topic of a number of recent research reports. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Oppenheimer dropped their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. BMO Capital Markets decreased their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Citigroup increased their price target on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Down 4.1 %

Shares of NASDAQ:NTLA opened at $9.19 on Wednesday. The stock has a market capitalization of $951.32 million, a PE ratio of -1.69 and a beta of 1.97. The firm’s 50 day moving average price is $10.23 and its 200-day moving average price is $14.40. Intellia Therapeutics, Inc. has a twelve month low of $8.30 and a twelve month high of $28.54.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 29,000 shares of company stock valued at $352,551. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.